Patents Assigned to Mesoblast, Inc.
  • Publication number: 20190201448
    Abstract: The present disclosure provides a method for treating an inflammatory neurological disease comprising administering a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.
    Type: Application
    Filed: January 4, 2019
    Publication date: July 4, 2019
    Applicant: Mesoblast, Inc.
    Inventor: Claude BERNARD
  • Publication number: 20190177685
    Abstract: The invention relates to multipotential expanded mesenchymal precursor progeny (MEMP's), characterised by the early developmental markers STRO-1bri and ALP. The present invention also relates to methods for producing MEMP's and to uses of MEMP's for therapeutic applications.
    Type: Application
    Filed: February 25, 2019
    Publication date: June 13, 2019
    Applicant: Mesoblast, Inc.
    Inventors: Stan Gronthos, Andrew Christopher William Zannettino
  • Patent number: 10220057
    Abstract: A method of enriching mesenchymal precursor cells including the step of enriching for cells based on at least two markers. The markers may be either i) the presence of markers specific for mesenchymal precursor cells, ii) the absence of markers specific for differentiated mesenchymal cells, or iii) expression levels of markers specific for mesenchymal precursor cells. The method may include a first solid phase sorting step utilizing MACS recognizing expression of the antigen to the STRO-1 Mab, followed by a second sorting step utilizing two color FACS to screen for the presence of high level STRO-1 antigen expression as well as the expression of VCAM-1.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: March 5, 2019
    Assignee: MESOBLAST, INC.
    Inventors: Paul Simmons, Stan Gronthos, Andrew Zannetino
  • Patent number: 10206951
    Abstract: The present disclosure provides a method for treating an inflammatory neurological disease comprising administering a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: February 19, 2019
    Assignee: MESOBLAST, INC.
    Inventor: Claude Bernard
  • Publication number: 20190046575
    Abstract: The present disclosure provides methods of treating or preventing respiratory condition and/or for treating an IgE-mediated allergy and/or for reducing an allergic response to an allergen and/or for inducing anergy to an allergen in a subject and/or improving lung function in a subject suffering from an allergy comprising administering to a subject a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.
    Type: Application
    Filed: July 16, 2018
    Publication date: February 14, 2019
    Applicant: Mesoblast, Inc.
    Inventors: Silviu Itescu, Ravi Krishnan, Peter Ghosh
  • Publication number: 20190030080
    Abstract: A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the mammal a population of cells enriched for STRO-1bright cells and/or progeny thereof and/or soluble factors derived therefrom.
    Type: Application
    Filed: September 14, 2018
    Publication date: January 31, 2019
    Applicant: Mesoblast, Inc.
    Inventors: Silviu Itescu, Michael David Schuster
  • Publication number: 20180369286
    Abstract: The present invention relates to methods of treating or preventing angiogenesis-related diseases by the administration of stem cells and/or progeny cells thereof.
    Type: Application
    Filed: October 19, 2017
    Publication date: December 27, 2018
    Applicant: Mesoblast, Inc.
    Inventor: Piroska Elizabeth Rakoczy
  • Patent number: 10159696
    Abstract: The present disclosure provides methods of treating or preventing obesity or causing weight loss or treating or preventing metabolic syndrome comprising administering to a subject a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: December 25, 2018
    Assignee: MESOBLAST, INC.
    Inventors: Ravi Krishnan, Silviu Itescu
  • Publication number: 20180303879
    Abstract: The present disclosure provides a method for treating or preventing a rheumatic disease, comprising administering a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.
    Type: Application
    Filed: April 17, 2018
    Publication date: October 25, 2018
    Applicant: MESOBLAST, INC.
    Inventors: Peter Ghosh, Silviu Itescu
  • Patent number: 10105394
    Abstract: A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the mammal a population of cells enriched for STRO-1bright cells and/or progeny thereof and/or soluble factors derived therefrom.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: October 23, 2018
    Assignee: MESOBLAST, INC.
    Inventors: Silviu Itescu, Michael David Schuster
  • Publication number: 20180237746
    Abstract: The invention relates to multipotential expanded mesenchymal precursor progeny (MEMP's), characterised by the early developmental markers STRO-1bri and ALP. The present invention also relates to methods for producing MEMP's and to uses of MEMP's for therapeutic applications.
    Type: Application
    Filed: December 19, 2017
    Publication date: August 23, 2018
    Applicant: Mesoblast, Inc.
    Inventors: Stan Gronthos, Andrew Christopher William Zannettino
  • Patent number: 10028979
    Abstract: The present disclosure provides methods of treating or preventing respiratory condition and/or for treating an IgE-mediated allergy and/or for reducing an allergic response to an allergen and/or for inducing anergy to an allergen in a subject and/or improving lung function in a subject suffering from an allergy comprising administering to a subject a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: July 24, 2018
    Assignee: MESOBLAST, INC.
    Inventors: Silviu Itescu, Ravi Krishnan, Peter Ghosh
  • Patent number: 9974812
    Abstract: The present disclosure provides a method for treating or preventing a rheumatic disease, comprising administering a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: May 22, 2018
    Assignee: MESOBLAST, INC
    Inventors: Peter Ghosh, Silviu Itescu
  • Patent number: 9968640
    Abstract: The present invention provides a method for improving pancreatic function in a subject in need thereof, the method comprising administering to the subject STRO-1+ cells and/or progeny cells thereof and/or soluble factors derived therefrom. The method of the invention is useful for treating and/or preventing and/or delaying the onset or progression of a disorder resulting from or associated with pancreatic dysfunction, e.g., resulting from abnormal endocrine or exocrine function of the pancreas.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: May 15, 2018
    Assignee: MESOBLAST, INC.
    Inventors: Silviu Itescu, Ravi Krishnan
  • Publication number: 20180009905
    Abstract: The present invention relates to the use of tissue non-specific alkaline phosphatase (TNAP) as a marker for identifying and/or isolating adult multipotential cells. The present invention also relates to cell populations enriched by methods of the present invention and therapeutic uses of these cells.
    Type: Application
    Filed: July 17, 2017
    Publication date: January 11, 2018
    Applicant: Mesoblast, Inc.
    Inventors: Stan Gronthos, Andrew Christopher William Zannettino, John Paul Simmons
  • Publication number: 20170274016
    Abstract: The present disclosure provides methods of increasing osteoblastic function in a subject, the method comprising systemically administering to the subject a population of stem cells and/or progeny thereof and/or soluble factors derived therefrom.
    Type: Application
    Filed: April 12, 2017
    Publication date: September 28, 2017
    Applicant: Mesoblast, Inc.
    Inventors: Silviu Itescu, Ravi Krishnan
  • Publication number: 20170258846
    Abstract: A method for suppressing T cell activation which comprises contacting a cell population comprising T cells in vitro or ex vivo with an effective amount of STRO-1+ cells and/or soluble factors derived therefrom to suppress T cell activation.
    Type: Application
    Filed: May 15, 2017
    Publication date: September 14, 2017
    Applicant: Mesoblast, Inc.
    Inventors: Silviu Itescu, Michael David Schuster
  • Publication number: 20170157181
    Abstract: This invention relates to a method for generating, repairing and/or maintaining connective tissue in a subject. In one embodiment, the invention relates to a method for generating, repairing and/or maintaining cartilage tissue in a subject. The present invention also relates to a method of treating and/or preventing a disease in a subject arising from degradation and inflammation of connective tissue.
    Type: Application
    Filed: June 9, 2016
    Publication date: June 8, 2017
    Applicant: Mesoblast, Inc.
    Inventor: Peter Ghosh
  • Patent number: 9642878
    Abstract: The present disclosure provides methods of increasing osteoblastic function in a subject, the method comprising systemically administering to the subject a population of stem cells and/or progeny thereof and/or soluble factors derived therefrom.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: May 9, 2017
    Assignee: MESOBLAST, INC.
    Inventors: Silviu Itescu, Ravi Krishnan
  • Publication number: 20170042945
    Abstract: The present invention provides a method for improving pancreatic function in a subject in need thereof, the method comprising administering to the subject STRO-1+ cells and/or progeny cells thereof and/or soluble factors derived therefrom. The method of the invention is useful for treating and/or preventing and/or delaying the onset or progression of a disorder resulting from or associated with pancreatic dysfunction, e.g., resulting from abnormal endocrine or exocrine function of the pancreas.
    Type: Application
    Filed: October 27, 2016
    Publication date: February 16, 2017
    Applicant: MESOBLAST, INC.
    Inventors: Silviu Itescu, Ravi Krishnan